These findings suggest that miR-34 mimics may hold significant promise as a novel molecular therapy for human pancreatic cancer with loss of p53–miR34, potentially via modulating pancreatic cancer stem cells. The gene discussed is TP53; the disease is pancreatic neoplasm.